Targeting p21-activated kinase 4 (PAK4) with pyrazolo[3,4-d]pyrimidine derivative SPA7012 attenuates hepatic ischaemia-reperfusion injury in mice

References

• Eltzschig HK, Eckle T. Ischemia and reperfusion–from mechanism to translation. Nat Med 2011;17:1391–401.
   PubMed Web of Science ®Google Scholar
• Konishi T, Lentsch AB. Hepatic ischemia/reperfusion: mechanisms of tissue injury, repair, and regeneration. Gene Expr 2017;17:277–87.
   PubMedGoogle Scholar
• Lentsch AB, Kato A, Yoshidome H, et al. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology 2000;32:169–73.
   PubMed Web of Science ®Google Scholar
• Kudoh K, Uchinami H, Yoshioka M, et al. Nrf2 activation protects the liver from ischemia/reperfusion injury in mice. Ann Surg 2014;260:118–27.
   PubMed Web of Science ®Google Scholar
• Lee LY, Harberg C, Matkowskyj KA, et al. Cell-specific overactivation of nuclear erythroid 2 p45-related factor 2-mediated gene expression in myeloid cells decreases hepatic ischemia/reperfusion injury. Liver Transpl 2016;22:1115–28.
   PubMed Web of Science ®Google Scholar
• Xu D, Xu M, Jeong S, et al. The role of Nrf2 in liver disease: novel molecular mechanisms and therapeutic approaches. Front Pharmacol 2018;9:1428.
   PubMed Web of Science ®Google Scholar
• Salazar M, Rojo AI, Velasco D, et al. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem 2006;281:14841–51.
   PubMed Web of Science ®Google Scholar
• Liu T, Lv YF, Zhao JL, et al. Regulation of Nrf2 by phosphorylation: consequences for biological function and therapeutic implications. Free Radic Biol Med 2021;168:129–41.
   PubMed Web of Science ®Google Scholar
• Mao Y, Han CY, Hao L, et al. PAK4 inhibition protects against liver ischemia/reperfusion injury: role of Nrf2 phosphorylation. Hepatology 2022;76:345–56.
   PubMed Web of Science ®Google Scholar
• Murray BW, Guo C, Piraino J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A 2010;107:9446–51.
   PubMed Web of Science ®Google Scholar
• Senapedis W, Crochiere M, Baloglu E, Landesman Y. Therapeutic potential of targeting PAK signaling. Anticancer Agents Med Chem 2016;16:75–88.
   PubMed Web of Science ®Google Scholar
• Rudolph J, Crawford JJ, Hoeflich KP, Wang W. Inhibitors of p21-activated kinases (PAKs). J Med Chem 2015;58:111–29.
   PubMed Web of Science ®Google Scholar
• Abu Aboud O, Chen CH, Senapedis W, et al. Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney cancer growth. Mol Cancer Ther 2016;15:2119–29.
   PubMed Web of Science ®Google Scholar
• Hao C, Zhao F, Song H, et al. Structure-based design of 6-chloro-4-aminoquinazoline-2-carboxamide derivatives as potent and selective p21-activated kinase 4 (PAK4) inhibitors. J Med Chem 2018;61:265–85.
   PubMed Web of Science ®Google Scholar
• Yu J, Lee HS, Lee SM, et al. Aggravation of post-ischemic liver injury by overexpression of A20, an NF-kappaB suppressor. J Hepatol 2011;55:328–36.
   PubMed Web of Science ®Google Scholar
• Zhang EY, Ha BH, Boggon TJ. PAK4 crystal structures suggest unusual kinase conformational movements. Biochim Biophys Acta Proteins Proteom 2018;1866:356–65.
   PubMed Web of Science ®Google Scholar
• Staben ST, Feng JA, Lyle K, et al. Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors. J Med Chem 2014;57:1033–45.
   PubMed Web of Science ®Google Scholar
• Fabbro D, Ruetz S, Buchdunger E, et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 2002;93:79–98.
   PubMed Web of Science ®Google Scholar
• Wang J, Koh HW, Zhou L, et al. Sirtuin 2 aggravates postischemic liver injury by deacetylating mitogen-activated protein kinase phosphatase-1. Hepatology 2017;65:225–36.
   PubMed Web of Science ®Google Scholar
• Bae UJ, Yang JD, Ka SO, et al. SPA0355 attenuates ischemia/reperfusion-induced liver injury in mice. Exp Mol Med 2014;46:e109.
   PubMed Web of Science ®Google Scholar
• Zuccotto F, Ardini E, Casale E, Angiolini M. Through the "gatekeeper door": exploiting the active kinase conformation. J Med Chem 2010;53:2681–94.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Jr., Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res 2020;152:104609.
   PubMed Web of Science ®Google Scholar
• Yi Z, Deng M, Scott MJ, et al. Immune-responsive gene 1/Itaconate activates nuclear factor erythroid 2-related factor 2 in hepatocytes to protect against liver ischemia-reperfusion injury. Hepatology 2020;72:1394–411.
   PubMed Web of Science ®Google Scholar
• Xin Y, Bai Y, Jiang X, et al. Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ss/Fyn pathway. Redox Biol 2018;15:405–17.
   PubMed Web of Science ®Google Scholar
• Ke B, Shen XD, Zhang Y, et al. KEAP1-NRF2 complex in ischemia-induced hepatocellular damage of mouse liver transplants. J Hepatol 2013;59:1200–7.
   PubMed Web of Science ®Google Scholar
• Mao Y, Han CY, Hao L, et al. p21-activated kinase 4 phosphorylates peroxisome proliferator-activated receptor g and suppresses skeletal muscle regeneration. J Cachexia Sarcopenia Muscle 2021;12:1776–88.
   PubMed Web of Science ®Google Scholar
• Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 2011;21:103–15.
   PubMed Web of Science ®Google Scholar
• Li X, Minden A. PAK4 functions in tumor necrosis factor (TNF) alpha-induced survival pathways by facilitating TRADD binding to the TNF receptor. J Biol Chem 2005;280:41192–200.
   PubMed Web of Science ®Google Scholar
• Ryu BJ, Lee H, Kim SH, et al. PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-kappaB, and beta-catenin signalings. Mol Cell Biochem 2014;389:69–77.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhang X, Wei N, et al. p21-activated kinase 4 as a switch between caspase-8 apoptosis and NF-kappaB survival signals in response to TNF-alpha in hepatocarcinoma cells. Biochem Biophys Res Commun 2018;503:3003–10.
   PubMed Web of Science ®Google Scholar
• Wang M, Gao Q, Chen Y, et al. PAK4, a target of miR-9-5p, promotes cell proliferation and inhibits apoptosis in colorectal cancer. Cell Mol Biol Lett 2019;24:58.
   PubMed Web of Science ®Google Scholar
• Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 2006;43:S31–S44.
   PubMed Web of Science ®Google Scholar